Net Sales are expected to increase by 11 percent Y-o-Y (up 4.6 percent Q-o-Q) to Rs 2,604.6 crore, according to Nirmal Bang.

Torrent Pharma Q3 PAT seen up 28.9% YoY to Rs 3,211 cr: Nirmal Bang

Net Sales are expected to increase by 14.1 percent Y-o-Y (up 4.8 percent Q-o-Q) to Rs 24,020 crore, according to Nirmal Bang.

Torrent Pharma Q1 PAT seen up 2.8% YoY to Rs 339.1 cr: ICICI Direct

Net Sales are expected to increase by 11 percent Y-o-Y (up 11.1 percent Q-o-Q) to Rs 2,367.8 crore, according to ICICI Direct.

Torrent Pharmaceuticals Q1 PAT seen up 1.4% YoY to Rs 334.5 cr: Prabhudas Lilladher

Net Sales are expected to increase by 6.9 percent Y-o-Y (up 7.1 percent Q-o-Q) to Rs 2,281.4 crore, according to Prabhudas Lilladher.

Torrent Pharma Q1 PAT seen up 34.2% YoY to Rs 430.8 cr: KRChoksey

Net Sales are expected to decrease by 5.8 percent Y-o-Y to Rs 1,837 crore, according to KRChoksey.

Torrent Pharma Q1 PAT seen up 10.8% YoY to Rs 355.7 cr: ICICI Direct

Net Sales are expected to increase by 7.7 percent Y-o-Y (up 14.3 percent Q-o-Q) to Rs 2,214.3 crore, according to ICICI Direct.

Torrent Pharma Q4 PAT may dip 1.9% YoY to Rs. 308 cr: Sharekhan

Net Sales are expected to increase by 4.6 percent Y-o-Y (up 1.5 percent Q-o-Q) to Rs. 2,000.7 crore, according to Sharekhan.

Torrent Pharma Q2 PAT seen up 8% YoY to Rs. 220.3 cr: Emkay

Net Sales are expected to increase by 9.4 percent Y-o-Y (up 2.5 percent Q-o-Q) to Rs. 2,073 crore, according to Emkay.

Torrent Pharma shares jump 6% as brokerages remain bullish after Q1 show

Nomura expects Torrent to record strong cash flow generation over the next three years

Torrent Pharmaceuticals Q4 PAT may dip 12.6% YoY to Rs. 199.3 cr: Kotak

Net Sales are expected to increase by 14.7 percent Y-o-Y (down 3.7 percent Q-o-Q) to Rs. 1,975.8 crore, according to Kotak.

Torrent Pharma Q3 PAT may dip 18.1% YoY to Rs. 199 cr: Sharekhan

Net Sales are expected to increase by 33.6 percent Y-o-Y (up 4.2 percent Q-o-Q) to Rs. 1,973 crore, according to Sharekhan.

Torrent Pharma Q3 PAT seen up 183.6% YoY to Rs. 164.5 cr: ICICI Direct

Net Sales are expected to increase by 31.9 percent Y-o-Y (up 2.9 percent Q-o-Q) to Rs. 1,948.3 crore, according to ICICI Direct.

Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila

For Lupin, Credit Suisse sees margin improving but weak Tamiflu season could be an overhang.

Torrent Pharma Q2 PAT may dip 5.4% YoY to Rs. 190 cr: HDFC Securities

Net Sales are expected to increase by 34.6 percent Y-o-Y (up 2.7 percent Q-o-Q) to Rs. 1,920 crore, according to HDFC Securities.

Torrent Pharma Q2 PAT may dip 18.4% YoY to Rs. 166.5 cr: Sharekhan

Net Sales are expected to increase by 31.9 percent Y-o-Y (up 0.7 percent Q-o-Q) to Rs. 1,884.8 crore, according to Sharekhan.

Torrent Pharma Q2 PAT may dip 13.2% YoY to Rs. 177 cr: ICICI Direct

Net Sales are expected to increase by 33 percent Y-o-Y (up 1.5 percent Q-o-Q) to Rs. 1900.4 crore, according to ICICI Direct.

Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz

Emkay Global, in its report, observed that cycling pressure in US market will start waning ahead, but structural pressures will still persist.

Torrent Pharmaceuticals Q1 PAT may dip 8.4% YoY to Rs. 172.2 cr: Kotak

Net Sales are expected to increase by 30.2 percent Y-o-Y (up 3.9 percent Q-o-Q) to Rs. 1,789.1 crore, according to Kotak.

Torrent Pharma Q4 PAT seen up 1.3% YoY to Rs. 210 cr: HDFC Securities

Net Sales are expected to increase by 19.7 percent Y-o-Y (up 16.2 percent Q-o-Q) to Rs. 1,720 crore, according to HDFC Securities.

Torrent Pharmaceuticals Q4 PAT may dip 37.3% YoY to Rs. 129.3 cr: Edelweiss

Net Sales are expected to increase by 11.5 percent Y-o-Y (up 8.3 percent Q-o-Q) to Rs. 1,599.4 crore, according to Edelweiss.

Torrent Pharmaceuticals Q2 PAT seen up 13.9% YoY to Rs. 235.7 cr: Kotak

Net Sales are expected to increase by 9.2 percent Y-o-Y (up 13.6 percent Q-o-Q) to Rs. 1560.8 crore, according to Kotak.

Torrent Pharma Q4 PAT may dip 8.3% to Rs 209.9 cr: ICICI Securities

Net Sales are expected to increase by 3.4 percent Q-o-Q (down 0.4 percent Y-o-Y) to Rs 1492.7 crore, according to ICICI Securities. Torrent Pharma to report net profit at 209.9 crore down 8.3% quarter-on-quarter.

Torrent Pharma Q3 PAT seen up 7.1% to Rs 220 cr: HDFC Securities

Net Sales are expected to increase by 3 percent Q-o-Q (down 4.4 percent Y-o-Y) to Rs 1470 crore, according to HDFC Securities.

Torrent Pharma Q3 PAT seen up 15% to Rs 238 cr: ICICI Securities

Net Sales are expected to increase by 5.5 percent Q-o-Q (down 2.1 percent Y-o-Y) to Rs 1507 crore, according to ICICI Securities.

Torrent Pharma Q2 profit seen down 52% on low operational income

Torrent Pharma's second quarter earnings are expected to decline due to high base in year-ago period. Profit is likely to sink 51.8 percent year-on-year to Rs 273.7 crore and revenue may fall 8.9 percent to Rs 1,540.7 crore in Q2, according to analysts polled by CNBC-TV18.